A Randomized, Double-masked, Parallel, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of SJP-0132 Eye Drops Compared With Placebo in Chinese Patients With Dry Eye Disease
Latest Information Update: 10 Jun 2025
At a glance
- Drugs SJP 0132 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
Most Recent Events
- 13 Jan 2025 Status changed from not yet recruiting to recruiting.
- 11 Dec 2024 New trial record